DV
Dividend Vision

UPB — Upstream Bio, Inc.

Upstream Bio, Inc. (UPB)

Total return is -58.4% over the past 1.8 years, 95.9 points behind SPY at 37.5%. Its deepest 1-year drawdown was 81.8%.

This fund tracks the upstream biopharmaceutical sector, focusing on equity exposure to companies engaged in drug discovery, development, and early-stage clinical research. With a recent inception date and limited publicly available data on distribution frequency and expense ratio, the fund appears designed for investors seeking growth-oriented exposure to the biotechnology industry rather than current income, as it carries no meaningful dividend yield profile.

UPB key facts

Asset type
Stock
Asset class
Equity
Inception date
10/10/2024
Last close
$7.07
Market cap
$379,851,520
Average volume
688200.0
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.90